BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26830055)

  • 21. Recent clinical trials of iodixanol.
    Erdogan A; Davidson CJ
    Rev Cardiovasc Med; 2003; 4 Suppl 5():S43-50. PubMed ID: 14668709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT) - a clinical problem in daily practice? A multicenter observational study.
    Lencioni R; Fattori R; Morana G; Stacul F
    Acta Radiol; 2010 Sep; 51(7):741-50. PubMed ID: 20707658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal safety of iodixanol.
    McCullough PA
    Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):655-61. PubMed ID: 17081087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media.
    Alexopoulos E; Spargias K; Kyrzopoulos S; Manginas A; Pavlides G; Voudris V; Lerakis S; McLean DS; Cokkinos DV
    Am J Med Sci; 2010 Jan; 339(1):25-30. PubMed ID: 19996728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrast media use in patients with chronic kidney disease undergoing coronary angiography: A systematic review and meta-analysis of randomized trials.
    Pandya B; Chalhoub JM; Parikh V; Gaddam S; Spagnola J; El-Sayegh S; Bogin M; Kandov R; Lafferty J; Bangalore S
    Int J Cardiol; 2017 Feb; 228():137-144. PubMed ID: 27863354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Reed MC; Moscucci M; Smith DE; Share D; LaLonde T; Mahmood SA; D'Haem C; McNamara R; Greenbaum A; Gurm HS
    J Invasive Cardiol; 2010 Oct; 22(10):467-72. PubMed ID: 20944185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast-induced nephropathy-choice of contrast agents to reduce renal risk.
    Katholi RE
    Am Heart Hosp J; 2009; 7(1):45-9. PubMed ID: 19742433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials.
    McCullough PA; Capasso P
    BMC Med Imaging; 2011 May; 11():12. PubMed ID: 21609484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effect of iso-osmolar versus low-osmolar contrast media on the incidence of contrast-induced acute kidney injury in diabetic patients: a systematic review and meta-analysis.
    Zhao F; Lei R; Yang SK; Luo M; Cheng W; Xiao YQ; Li XW; Guo J; Duan SB
    Cancer Imaging; 2019 Jun; 19(1):38. PubMed ID: 31215488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relative renal safety of iodixanol compared with low-osmolar contrast media.
    Cantor E; Lim L
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1163-4; author reply 1164. PubMed ID: 19926063
    [No Abstract]   [Full Text] [Related]  

  • 33. Ioxaglate Versus IoDixanol for the Prevention of Contrast-Induced Nephropathy: The IDPC Trial.
    Freitas RAP; Tanajura LF; Mehran R; ChamiƩ D; Chaves A; Centemero M; Braga S; Costa R; Cao D; Sousa A; Feres F; Costa JR
    J Invasive Cardiol; 2023 Jun; 35(6):E281-E290. PubMed ID: 37220640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrotoxicity of contrast media following cardiac angiography: pathogenesis, clinical course, and preventive measures, including the role of low-osmolality contrast media.
    Spinler SA; Goldfarb S
    Ann Pharmacother; 1992 Jan; 26(1):56-64. PubMed ID: 1606346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.
    Bagshaw SM; Ghali WA
    Arch Intern Med; 2005 May; 165(10):1087-93. PubMed ID: 15911721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of intravenous iodinated contrast media in Italy.
    Iannazzo S; Vandekerckhove S; De Francesco M; Nayak A; Ronco C; Morana G; Valentino M
    Int J Technol Assess Health Care; 2014 Jan; 30(1):69-77. PubMed ID: 24485022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of contrast-induced nephropathy for patients receiving intravenous vs. intra-arterial iodixanol administration.
    Tong GE; Kumar S; Chong KC; Shah N; Wong MJ; Zimmet JM; Wang ZJ; Yee J; Fu Y; Yeh BM
    Abdom Radiol (NY); 2016 Jan; 41(1):91-9. PubMed ID: 26830615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials.
    Dong M; Jiao Z; Liu T; Guo F; Li G
    J Nephrol; 2012; 25(3):290-301. PubMed ID: 22252847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.
    Terrenato I; Sperati F; Musicco F; Pozzi AF; di Turi A; Caterino M; de Lutio di Castelguidone E; Setola SV; Bellomi M; Neumaier CE; Conti L; Cigliana G; Merola R; Antenucci A; Orlandi G; Giordano A; Barba M; Canitano S
    J Cell Physiol; 2018 Mar; 233(3):2572-2580. PubMed ID: 28777459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.